Literature DB >> 17374994

Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2.

Robert K Dearth1, Xiaojiang Cui, Hyun-Jung Kim, Darryl L Hadsell, Adrian V Lee.   

Abstract

Insulin receptor substrates (IRSs) are adaptor proteins that link signaling from upstream activators to multiple downstream effectors to modulate normal growth, metabolism, survival, and differentiation. Recent cell culture studies have shown that IRSs can interact with, and are functionally required for, the transforming ability of many oncogenes. Consistent with this, IRSs are elevated and hyperactive in many human tumors. IRSs respond to many extracellular signals that are critical for mammary gland development, and we have shown that IRSs disrupt normal mammary acini formation in vitro, and cause mammary tumorigenesis and metastasis in vivo. In this review we will discuss the role of IRSs in both transformation and cancer progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374994     DOI: 10.4161/cc.6.6.4035

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  86 in total

Review 1.  Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.

Authors:  Wade T Iams; Christine M Lovly
Journal:  Clin Cancer Res       Date:  2015-10-01       Impact factor: 12.531

2.  Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.

Authors:  Adrienne S McCampbell; Heather A Harris; Judy S Crabtree; Richard C Winneker; Cheryl L Walker; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

3.  Genomic aberrations in pediatric diffuse intrinsic pontine gliomas.

Authors:  Katherine E Warren; Keith Killian; Miia Suuriniemi; Yonghong Wang; Martha Quezado; Paul S Meltzer
Journal:  Neuro Oncol       Date:  2011-11-07       Impact factor: 12.300

Review 4.  Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.

Authors:  Richard Marcotte; William J Muller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-24       Impact factor: 2.673

Review 5.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

6.  Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.

Authors:  Yinfei Tan; Mitchell Cheung; Jianming Pei; Craig W Menges; Andrew K Godwin; Joseph R Testa
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

7.  Overexpression of insulin receptor substrate-4 is correlated with clinical staging in colorectal cancer patients.

Authors:  Patricia Sanmartín-Salinas; M Val Toledo-Lobo; Fernando Noguerales-Fraguas; María-Encarnación Fernández-Contreras; Luis G Guijarro
Journal:  J Mol Histol       Date:  2017-11-28       Impact factor: 2.611

8.  Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity.

Authors:  Adam S Potter; Angelo J Casa; Adrian V Lee
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

9.  Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer.

Authors:  Akiko Hanyuda; Sun A Kim; Alejandro Martinez-Fernandez; Zhi Rong Qian; Mai Yamauchi; Reiko Nishihara; Teppei Morikawa; Xiaoyun Liao; Kentaro Inamura; Kosuke Mima; Yin Cao; Xuehong Zhang; Kana Wu; Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs; Ramesh A Shivdasani; Shuji Ogino
Journal:  Ann Surg Oncol       Date:  2015-11-17       Impact factor: 5.344

10.  EPO receptor circuits for primary erythroblast survival.

Authors:  Pradeep Sathyanarayana; Arvind Dev; Jing Fang; Estelle Houde; Olga Bogacheva; Oleg Bogachev; Madhu Menon; Sarah Browne; Anamika Pradeep; Christine Emerson; Don M Wojchowski
Journal:  Blood       Date:  2008-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.